Comparing of PolarityTE Inc. (PTE) and ANI Pharmaceuticals Inc. (NASDAQ:ANIP)

This is a contrast between PolarityTE Inc. (NASDAQ:PTE) and ANI Pharmaceuticals Inc. (NASDAQ:ANIP) based on their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation. The two companies are Biotechnology and they also compete with each other.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
PolarityTE Inc. 1.56M 212.75 74.16M -5.22 0.00
ANI Pharmaceuticals Inc. 191.74M 3.62 N/A 1.18 46.66

Table 1 highlights PolarityTE Inc. and ANI Pharmaceuticals Inc.’s top-line revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 provides us PolarityTE Inc. and ANI Pharmaceuticals Inc.’s return on assets, return on equity and net margins.

Net Margins Return on Equity Return on Assets
PolarityTE Inc. -4,753.85% 0% 0%
ANI Pharmaceuticals Inc. 0.00% 0.2% 0.1%

Risk and Volatility

PolarityTE Inc.’s current beta is 1.19 and it happens to be 19.00% more volatile than Standard & Poor’s 500. Competitively, ANI Pharmaceuticals Inc.’s 145.00% volatility makes it more volatile than Standard & Poor’s 500, because of the 2.45 beta.

Liquidity

The Current Ratio of PolarityTE Inc. is 18.5 while its Quick Ratio stands at 18.4. The Current Ratio of rival ANI Pharmaceuticals Inc. is 3.3 and its Quick Ratio is has 2.5. PolarityTE Inc. is better equipped to clear short and long-term obligations than ANI Pharmaceuticals Inc.

Analyst Ratings

The Recommendations and Ratings for PolarityTE Inc. and ANI Pharmaceuticals Inc. are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
PolarityTE Inc. 0 0 0 0.00
ANI Pharmaceuticals Inc. 0 0 1 3.00

On the other hand, ANI Pharmaceuticals Inc.’s potential upside is 19.41% and its consensus price target is $70.

Institutional and Insider Ownership

Institutional investors owned 54.2% of PolarityTE Inc. shares and 84.7% of ANI Pharmaceuticals Inc. shares. Insiders owned roughly 35% of PolarityTE Inc.’s shares. Comparatively, ANI Pharmaceuticals Inc. has 0.4% of it’s share owned by insiders.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
PolarityTE Inc. -4.26% 1% -26.16% -49.19% -51.72% -38.95%
ANI Pharmaceuticals Inc. -1.21% -0.63% -0.62% -17.28% -18.38% -14.79%

For the past year PolarityTE Inc. was more bearish than ANI Pharmaceuticals Inc.

Summary

On 9 of the 11 factors ANI Pharmaceuticals Inc. beats PolarityTE Inc.

PolarityTE, Inc. operates as a biotechnology and regenerative biomaterials company in the United States. The company focuses on discovering, designing, and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences. PolarityTE, Inc. is headquartered in Salt Lake City, Utah.

ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States. It focuses on producing controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. The company offers Erythromycin Ethylsuccinate to treat infections; Esterified Estrogen with Methyltestosterone for treating vasomotor symptoms of menopause; Etodolac to treat pain caused by osteoarthritis, rheumatoid arthritis, and other conditions; Fenofibrate for treating hypercholesterolemia; Flecainide to treat arrhythmia; Fluvoxamine for treating obsessive-compulsive and social anxiety disorders; and Hydrocortisone Enema and Cortenema to treat ulcerative colitis. It also provides Hydrocortisone Rectal Cream to treat inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses; Lithium Carbonate ER and Lithobid for bipolar disorder; Mesalamine Enema to treat distal ulcerative colitis, proctosigmoiditis, or proctitis; Methazolamide to treat ocular conditions; and Metoclopramide and Reglan to treat gastroesophageal reflux. In addition, the company offers Nilutamide to treat metastatic prostate cancer; Nimodipine that reduces the ischemic deficits in patients with subarachnoid hemorrhage; Opium Tincture to treat diarrhea; Oxycodone capsules and oral solution for pain; Propafenone to treat arrhythmia; Propranolol ER and Inderal LA for managing hypertension in patients with angina pectoris; and Vancomycin and Vancocin for use in treating C. difficile-associated diarrhea and enterocolitis. Further, it provides contract manufacturing services for other pharmaceutical companies. The company markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. ANI Pharmaceuticals, Inc. is headquartered in Baudette, Minnesota.